Starpharma Holdings Limited

ASX:SPL Stock Report

Market Cap: AU$53.6m

Starpharma Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Starpharma Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth27.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

May 16
Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20
Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18
Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22
We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21
Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Jan 26
We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Jun 21
We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

May 16
Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02
Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10
Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20
Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28
Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07
How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Starpharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:SPL - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202311-8-7-6N/A
9/30/20237-12-10-10N/A
6/30/20234-16-14-14N/A
3/31/20235-16-11-10N/A
12/31/20225-16-8-7N/A
9/30/20225-16-11-10N/A
6/30/20225-16-14-13N/A
3/31/20225-17-18-17N/A
12/31/20214-18-21-21N/A
9/30/20214-19-18-18N/A
6/30/20213-20-15-15N/A
3/31/20213-19-13-13N/A
12/31/20203-19-11-11N/A
9/30/20205-17-11-11N/A
6/30/20207-15-11-11N/A
3/31/20207-14-10-10N/A
12/31/20198-13-8-8N/A
9/30/20195-14-10-9N/A
6/30/20193-14-11-10N/A
3/31/20194-13-9-8N/A
12/31/20184-11-7-6N/A
9/30/20185-11-9-8N/A
6/30/20185-10-11-10N/A
3/31/20185-12N/AN/AN/A
12/31/20174-13-19-18N/A
9/30/20174-14N/A-18N/A
6/30/20174-15N/A-17N/A
12/31/20161-20N/A-20N/A
9/30/20163-20N/A-19N/A
6/30/20165-21N/A-18N/A
3/31/20165-22N/A-17N/A
12/31/20155-20N/A-16N/A
9/30/20153-20N/A-15N/A
6/30/20152-19N/A-14N/A
3/31/20151-18N/A-11N/A
12/31/20141-18N/A-9N/A
9/30/20141-16N/A-9N/A
6/30/20141-15N/A-10N/A
3/31/20142-12N/A-8N/A
12/31/20132-9N/A-6N/A
9/30/20132-7N/A-8N/A
6/30/20132-5N/A-10N/A
3/31/20133-8N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SPL's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if SPL's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if SPL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SPL's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if SPL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.